TW550267B - Novel pentasaccharides, processes for their preparation and pharmaceutical compositions containing them - Google Patents
Novel pentasaccharides, processes for their preparation and pharmaceutical compositions containing them Download PDFInfo
- Publication number
- TW550267B TW550267B TW088100711A TW88100711A TW550267B TW 550267 B TW550267 B TW 550267B TW 088100711 A TW088100711 A TW 088100711A TW 88100711 A TW88100711 A TW 88100711A TW 550267 B TW550267 B TW 550267B
- Authority
- TW
- Taiwan
- Prior art keywords
- methyl
- tri
- sulfo
- glucopyranosyl
- compound
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 12
- 238000002360 preparation method Methods 0.000 title description 34
- 238000000034 method Methods 0.000 title description 14
- 150000003839 salts Chemical class 0.000 claims abstract description 22
- 239000002253 acid Substances 0.000 claims description 35
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 31
- 239000004480 active ingredient Substances 0.000 claims description 21
- -1 methyl- Chemical group 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 10
- 229910000831 Steel Inorganic materials 0.000 claims description 8
- 239000010959 steel Chemical class 0.000 claims description 8
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical class N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 5
- 229960002442 glucosamine Drugs 0.000 claims description 5
- 206010053567 Coagulopathies Diseases 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000001858 anti-Xa Effects 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 208000015294 blood coagulation disease Diseases 0.000 claims description 2
- 239000003765 sweetening agent Substances 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims 1
- 150000002505 iron Chemical class 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 125000003132 pyranosyl group Chemical group 0.000 claims 1
- 235000021092 sugar substitutes Nutrition 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 abstract description 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract description 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 230000002378 acidificating effect Effects 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000000129 anionic group Chemical group 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 84
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 42
- 150000001875 compounds Chemical class 0.000 description 40
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 32
- 239000000243 solution Substances 0.000 description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 32
- 239000000203 mixture Substances 0.000 description 27
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 26
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 24
- 230000002079 cooperative effect Effects 0.000 description 19
- 239000011541 reaction mixture Substances 0.000 description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 17
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 14
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 14
- 238000004587 chromatography analysis Methods 0.000 description 14
- 238000004809 thin layer chromatography Methods 0.000 description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 13
- 238000011049 filling Methods 0.000 description 13
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 13
- 239000000377 silicon dioxide Substances 0.000 description 13
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 239000012074 organic phase Substances 0.000 description 12
- 238000003756 stirring Methods 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
- 239000002243 precursor Substances 0.000 description 9
- 230000002785 anti-thrombosis Effects 0.000 description 8
- IIEWJVIFRVWJOD-UHFFFAOYSA-N ethyl cyclohexane Natural products CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 description 8
- 229920005654 Sephadex Polymers 0.000 description 7
- 239000012507 Sephadex™ Substances 0.000 description 7
- 239000003146 anticoagulant agent Substances 0.000 description 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 7
- 235000019341 magnesium sulphate Nutrition 0.000 description 7
- 235000000346 sugar Nutrition 0.000 description 7
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000000262 chemical ionisation mass spectrometry Methods 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 229920001542 oligosaccharide Polymers 0.000 description 6
- 150000002482 oligosaccharides Chemical class 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- 108010074860 Factor Xa Proteins 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 150000001768 cations Chemical class 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 159000000000 sodium salts Chemical class 0.000 description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 4
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 150000002148 esters Chemical group 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- 229960002897 heparin Drugs 0.000 description 4
- 239000002808 molecular sieve Substances 0.000 description 4
- 150000002772 monosaccharides Chemical group 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- AKEJUJNQAAGONA-UHFFFAOYSA-N sulfur trioxide Chemical compound O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 3
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 3
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- 125000003535 D-glucopyranosyl group Chemical group [H]OC([H])([H])[C@@]1([H])OC([H])(*)[C@]([H])(O[H])[C@@]([H])(O[H])[C@]1([H])O[H] 0.000 description 3
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 3
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 229920001499 Heparinoid Polymers 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- AEMOLEFTQBMNLQ-HNFCZKTMSA-N L-idopyranuronic acid Chemical compound OC1O[C@@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-HNFCZKTMSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 3
- 108090000190 Thrombin Proteins 0.000 description 3
- 230000002429 anti-coagulating effect Effects 0.000 description 3
- 239000003114 blood coagulation factor Substances 0.000 description 3
- 229940125810 compound 20 Drugs 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 3
- 239000002554 heparinoid Substances 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 150000004044 tetrasaccharides Chemical class 0.000 description 3
- 229960004072 thrombin Drugs 0.000 description 3
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 2
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 2
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
- XHTUOWXUBNMVEU-UHFFFAOYSA-N 1-benzoyl-5-ethyl-5-(3-methylbutyl)-1,3-diazinane-2,4,6-trione Chemical compound O=C1C(CC)(CCC(C)C)C(=O)NC(=O)N1C(=O)C1=CC=CC=C1 XHTUOWXUBNMVEU-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 2
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000011097 chromatography purification Methods 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 229940126142 compound 16 Drugs 0.000 description 2
- 229940126086 compound 21 Drugs 0.000 description 2
- 229940125833 compound 23 Drugs 0.000 description 2
- 229940125846 compound 25 Drugs 0.000 description 2
- 229940125851 compound 27 Drugs 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 150000002009 diols Chemical class 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 2
- 229940097043 glucuronic acid Drugs 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229940025770 heparinoids Drugs 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- AEMOLEFTQBMNLQ-CLQWQSTFSA-N l-iduronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O AEMOLEFTQBMNLQ-CLQWQSTFSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 230000019635 sulfation Effects 0.000 description 2
- 238000005670 sulfation reaction Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 150000004043 trisaccharides Chemical class 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 1
- ZYZCALPXKGUGJI-DDVDASKDSA-M (e,3r,5s)-7-[3-(4-fluorophenyl)-2-phenyl-5-propan-2-ylimidazol-4-yl]-3,5-dihydroxyhept-6-enoate Chemical compound C=1C=C(F)C=CC=1N1C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C(C(C)C)N=C1C1=CC=CC=C1 ZYZCALPXKGUGJI-DDVDASKDSA-M 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- HEWZVZIVELJPQZ-UHFFFAOYSA-N 2,2-dimethoxypropane Chemical compound COC(C)(C)OC HEWZVZIVELJPQZ-UHFFFAOYSA-N 0.000 description 1
- HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- VEXJSFASSDRQRD-UHFFFAOYSA-N 2-methylbutanimidamide Chemical compound CCC(C)C(N)=N VEXJSFASSDRQRD-UHFFFAOYSA-N 0.000 description 1
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 description 1
- JRLTTZUODKEYDH-UHFFFAOYSA-N 8-methylquinoline Chemical group C1=CN=C2C(C)=CC=CC2=C1 JRLTTZUODKEYDH-UHFFFAOYSA-N 0.000 description 1
- 102100033757 Acyl-coenzyme A thioesterase 11 Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 101150041968 CDC13 gene Proteins 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- DCERHCFNWRGHLK-UHFFFAOYSA-N C[Si](C)C Chemical compound C[Si](C)C DCERHCFNWRGHLK-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 240000008892 Helianthus tuberosus Species 0.000 description 1
- 235000003230 Helianthus tuberosus Nutrition 0.000 description 1
- 101000801224 Homo sapiens Acyl-coenzyme A thioesterase 11 Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000183024 Populus tremula Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- VVTJCGXUEVKQPZ-UHFFFAOYSA-L S(=O)(=O)([O-])[O-].[Mg+2].[Bi+3] Chemical compound S(=O)(=O)([O-])[O-].[Mg+2].[Bi+3] VVTJCGXUEVKQPZ-UHFFFAOYSA-L 0.000 description 1
- JLHODUDOIRFKCB-UHFFFAOYSA-J S(=O)(=O)([O-])[O-].[Os+4].S(=O)(=O)([O-])[O-] Chemical compound S(=O)(=O)([O-])[O-].[Os+4].S(=O)(=O)([O-])[O-] JLHODUDOIRFKCB-UHFFFAOYSA-J 0.000 description 1
- 229930182475 S-glycoside Natural products 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- DRUIESSIVFYOMK-UHFFFAOYSA-N Trichloroacetonitrile Chemical compound ClC(Cl)(Cl)C#N DRUIESSIVFYOMK-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 102220589754 YjeF N-terminal domain-containing protein 3_G25F_mutation Human genes 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- MJOQJPYNENPSSS-XQHKEYJVSA-N [(3r,4s,5r,6s)-4,5,6-triacetyloxyoxan-3-yl] acetate Chemical compound CC(=O)O[C@@H]1CO[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O MJOQJPYNENPSSS-XQHKEYJVSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- YFHNDHXQDJQEEE-UHFFFAOYSA-N acetic acid;hydrazine Chemical compound NN.CC(O)=O YFHNDHXQDJQEEE-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- HBNBMOGARBJBHS-UHFFFAOYSA-N dimethylarsane Chemical compound C[AsH]C HBNBMOGARBJBHS-UHFFFAOYSA-N 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229940046240 glucomannan Drugs 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 150000002301 glucosamine derivatives Chemical class 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000000937 glycosyl acceptor Substances 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000002634 heparin fragment Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- OTCKOJUMXQWKQG-UHFFFAOYSA-L magnesium bromide Chemical compound [Mg+2].[Br-].[Br-] OTCKOJUMXQWKQG-UHFFFAOYSA-L 0.000 description 1
- 229910001623 magnesium bromide Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940062135 magnesium thiosulfate Drugs 0.000 description 1
- TZKHCTCLSRVZEY-UHFFFAOYSA-L magnesium;dioxido-oxo-sulfanylidene-$l^{6}-sulfane Chemical compound [Mg+2].[O-]S([O-])(=O)=S TZKHCTCLSRVZEY-UHFFFAOYSA-L 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- VJMRKWPMFQGIPI-UHFFFAOYSA-N n-(2-hydroxyethyl)-5-(hydroxymethyl)-3-methyl-1-[2-[[3-(trifluoromethyl)phenyl]methyl]-1-benzothiophen-7-yl]pyrazole-4-carboxamide Chemical compound OCC1=C(C(=O)NCCO)C(C)=NN1C1=CC=CC2=C1SC(CC=1C=C(C=CC=1)C(F)(F)F)=C2 VJMRKWPMFQGIPI-UHFFFAOYSA-N 0.000 description 1
- SVEUVITYHIHZQE-UHFFFAOYSA-N n-methylpyridin-2-amine Chemical compound CNC1=CC=CC=N1 SVEUVITYHIHZQE-UHFFFAOYSA-N 0.000 description 1
- 230000014508 negative regulation of coagulation Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 229910021332 silicide Inorganic materials 0.000 description 1
- FVBUAEGBCNSCDD-UHFFFAOYSA-N silicide(4-) Chemical compound [Si-4] FVBUAEGBCNSCDD-UHFFFAOYSA-N 0.000 description 1
- BABPEPRNSRIYFA-UHFFFAOYSA-N silyl trifluoromethanesulfonate Chemical compound FC(F)(F)S(=O)(=O)O[SiH3] BABPEPRNSRIYFA-UHFFFAOYSA-N 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical compound C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 1
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003569 thioglycosides Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- IMRYETFJNLKUHK-UHFFFAOYSA-N traseolide Chemical compound CC1=C(C(C)=O)C=C2C(C(C)C)C(C)C(C)(C)C2=C1 IMRYETFJNLKUHK-UHFFFAOYSA-N 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-O triethylammonium ion Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 231100000925 very toxic Toxicity 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 229920006163 vinyl copolymer Polymers 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
- C08B37/0078—Degradation products
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Polymers & Plastics (AREA)
- Materials Engineering (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Description
經濟部中央標準局員工消費合作社印製 550267 A7 > __B7 五、發明説明(1 ) 本發明係關於五糖,其製法及包含彼等之醫藥組合物。 肝素是葡糖胺聚糖系的一種多糖,其抗血凝性質是已知 的。現已知(I· Bjfirk and U. Lindahl,Molecular and Cell Biochemistry,1982, Dr· W. Junk Publishers-Netherlands)血 液凝固是一複雜的生理現象。有些刺激,如接觸活化及組 織因子,引發血漿内一連串凝血因子的相繼活化。不管刺 激的性質爲何,最終步驟是相同的,活化的X因予(X a )使 因子II(也稱作凝血酶原)活化,此被活化了的因子J J (即子 Ila,也稱作凝血酶)使可溶性纖維蛋白原部分蛋白酶解增 加,釋出不溶性纖維蛋白,此爲血凝塊主要成分之一。 在正常生理條件下,凝血因子的活動是受蛋白質如抗凝血 酶III (AT III)及肝素輔因子π (CH II)的調節,這類蛋白質是 存在於血漿内的。AT III對一些凝血因子,特別是對因子又壮 及Ila,發揮抑制活性。 疋以,因子X a或Ila的抑制是取得抗凝血及抗血检活動的 幸又佳方法,因爲,不論引發刺激爲何,此二種因子都涉及 血凝的最後二個步驟。 如 P· Sinay等於Carbohydrate Research 1984,132 C5 所述的 一種五糖代表結合至ΑΤ ΠΙ所需的最小肝素排序。十五年以 前此化合物即可全由化學合成製得。 自那時以後,文獻上即曾敘述有多種全由化學合成的寡糖 具有抗血栓抗血凝活性。 /PWM84,999號專利説明由糖醛酸(葡糖醛酸或艾杜糖醛酸) 早糖單位及葡糖胺構成的衍生物具有益的抗血栓性質。除 -4- i紙張尺度標準(c叫機格(~----- (請先閲讀背面之注意事項^^寫本頁)
I 550267 A7 B7 經濟部中央標準局員工消費合作社印製 五、發明説明(2 ) 了由羥基構成的取代基外,此等化合物還含有N-硫酸酯’ N-乙醯基,及某些情形下,此等異頭羥基係以甲氧基所代替。 專利申請案EP 0,165,134也敘述具抗血栓活性的合成寡 糖。專利申諳案EP 0,301,618也曾敘述過由糖醛酸單糖單位 及葡糖胺所構成,並於葡糖胺單位之3 -位上含有〇 -硫酸酯 的此類化合物。此等化合物具有力的抗血栓及抗血凝性 質。EP 0,454,220號專利説明醛酸衍生物及葡糖衍生物,此 等衍生物含Ο -烷基或〇 -硫酸酯作爲取代基。後一類化合物 也有抗血栓及抗血凝性質。 EP 0,529,175也敘述過硫酸化的葡糖胺類聚糖衍生物,其 中N -硫鹽酯,N -醋酸酯或羥基官能基係以烷氧基,芳基氧 基,芳烷氧基或〇 -硫酸酯所取代。此等化合物具有益的抗 血栓性質。後一類化合物並是平滑肌細胞增殖抑制劑。 Angew. Chem. Int· Ed. Engl· 1993, 32, 3, 434-436敘述過一 類寡糖,特別是五糖,其類似於結合至AT_III所需的最小肝 素排序。此等化合物含葡糖醛酸或葡葡糖單位,其羥基官 能度係以0 -硫酸酯或0 _甲基所取代。 自那以後已有許有關五糖的研究,文獻上已指出L -杜糖 醛酸單位G之構象在產物的活性上扮演重要角色。已説明過 單位G有數種構象態(4(^,七4,2SQ),有人並認爲此種構象 上的彈性在含L-艾杜糖醛酸的產物的生物活性是必需的(B. Casu, M. Petitou, A. Provasoli and P. Sinaij, Conformational flexibility: a new concept for explaining binding and biological properties of iduronic acid-containing glycosamino-glycans. -5- (請先閱讀背面之注意事項寫本頁) 装· >項^||寫太 訂
本紙張尺度適用中國國家標隼(CNS ) A4規格(210X 297公釐) 550267 A7 B7 五、發明説明(3
Trends Biochem. Sci. 1988, 13, 221-225)。 現已令人驚奇地發現,以伸^充基橋取代〇_烷基之一,因 而鎖住L-艾杜糖醛酸的構型,可製得具有益生物學性質的 寡糖,雖則這樣製成的寡糖缺乏構型彈性。此爲本發明化合 物不同於文獻上説明的其他合成類肝素(heparin〇ids)的原 因,重點在於新穎構造及其強效且無法預期的生物學性質。 本發明化合物是五糖,其中!_艾杜糖醛酸單位G是所,,鎖住 的n 2SG構象,及其中1>_葡糖醛酸單位E是視需要於弘位有 乙基此等化合物具有很強的抗因子X a活性及高at III親 合性。 本發明主題是,更特別地説,酸形式的五糖及其醫藥上可 接受的鹽,具有一或多個醫藥上可接受的陽離子,其因離 子形式如式(I):
G 〇 0
〇 ΟΜβ 其中: (I) 經濟部中央標準局員工消費合作社印製
Ri代表(cvc3)烷基; R代表氫或-so3-,(cvc3)烷基或(c2-c3)醯基; τ代表氫或乙基; η代表1或2。 本發明包括酸形式的五糖或其醫藥上可接受的鹽。於酸形 -6 - 本紙張尺度適用中國國家標準(CNS ) Α4規格(210X297公釐) 550267 A7 B7 五、發明説明(4 ) 式時,-COCT及-S03-官能度分別是-COOH及-S03H的形式。 ”本發明五糖的醫藥上可接受的鹽”意爲這樣的五糖,其 中一或多個- C00·及/或-S03-官能度是離子地結合於醫藥上 可接受的金屬陽離子上。 本發明較佳的鹽是這樣的鹽,其中陽離子是選自驗金屬陽 離子,尤佳是此等陽離子是Na+或K+。 本發明的主題也是製備本發明五糖的方法,其特點是製備 單位G前體,將此單位G前體偶合於單位Η前體上生成GH前 體,最終藉: 或是偶合GH前體與DEF前體, 或是偶合GH前體與EF前體,然後再加上D,製得五糖。 任何G,Η,EF,或DEF前體都可使用。就是説,根據本發 明方法,可製得有一般所住的構形的單位G的整個五糖系。 上述製法是本發明較佳製法。但本發明五糖也可用糖化學 所已知的其他方法製備,特別是以於羥基上及視需要於羧 基(如果有的話)含有如T.W. Green於Protective Groups in Organic Synthesis(Wiley,Ν.Υ· 1981)所述的保護基的單糖與 另一保護的單糖,生成雙糖,然後再與另一經保護的單糖 反應,生成經保護的三糖,由此三糖可製得經保護的四 糖,然後製成經保護的五糖。 然後將此經保護的五糖去保護並視要硫酸化,或者是作部 分取保護,然後硫酸化,然後再去保護,以製得本發明化 合物。 此類製法是糖化學已知的,也見於G· Jaurand等於 本紙張尺度適用中國國家標举(CNS ) A4規格(210X297公釐) (請先閱讀背面之注意事 裝— :寫本頁)
經濟部中央標準局員工消費合作社印製 550267
5 A7 B7 五、發明説明(
Bioorganic and Medicinal Chemistry Letters 1992, 2,9,897-900及J. Basten等於Bioorganic and Medicinal Chemistry Letters 1992,2,9,905-910,及 M. Petitou and C.A.A· van Boeckel 於 ’’Chemical synthesis of heparin fragment and analogues” 203-210 - Process in the chemistry of organic natural products, Ed. Springer Verlag Vienna - Ν·Υ. 1992所述方法0 上述製法可製得鹽形式的本發明化合物。要製得對應的酸 時,將鹽形式的本發明化合物酸形式的陽離子交換樹脂接 觸即可製得。 然後將酸形式的本發明化合物用鹼中和即可製得所需的 鹽0 這樣作時,可用無機或有機鹼製得醫藥上可接受的鹽。 較佳是用氫氧化鈉,氫氧化鉀,或氫氧化鎂。本發明五糖 的鈉及鈣鹽是是較佳的鹽。 本發明主題的化合物具有優良的藥理學及生化學性質。更 特定地説,其具有抗Xa因子活性,對AT III有大親合性。 如前所述,在凝血過程中Xa因子活化凝血酶原成爲凝血 酶,此凝血酶又使溶解的纖維蛋白原作蛋白酶解釋出不溶 解的纖維蛋白這一血凝塊的主要成分。是以,Xa因子的抑 制是較佳的取得抗血凝及抗血栓活性的方法。本發明產物 的抗Xa因子活性是於pH 7根據Teien A.N.及Lie M.於 Thrombosis Research 1997,10,399-410所述方法評估,顯示 本發明產物所具有的抗Xa活性等於或大於已知的合成類肝 素。本發明五糖,其陰離子如式(I)所示,對AT III的親合性 -8- 本紙張尺度適用中國國家標準(CNS ) A4規格(NOX297公釐)
550267 A7 B7 __- 經濟部中央標準局員工消費合作社印製 五、發明説明(6 ) 係以分光熒光法在D. Atha等於Biochemistry 1987, 26 6454- 5461所述方法測定。試驗結果顯示,本發明化合物對Ατ爪 有較大的親令性。 此外,此等化合物的總抗血栓活性是以小鼠作靜脈停滯及 用欺血激酶拫據 J. Reyers 等於 Thrombosis Research 1980,18, 669-674所述方法評估。本發明化合物Ed5。至少約與已知的 類肝素相等或更小。是以本發明化合物有有益的特異性作 用及有益的减及抗血检活性。 本發明化合物用於製備供非經腸給予的醫藥組合物。 本發明化合物毒性很低:作爲藥物使用其毒性是完全相容 的。 本發明化合物是分安定的,是以特別適於作爲藥物的活性 成分。 本發明也包括含本發明化合物或其醫藥上的鹽作爲活性成 分及視需要與其混合的一和多種惰性的及適宜的賦形劑的 醫藥組合物。 於每一單位劑量中活性成分的量適於作爲每曰劑量。每一 單位劑量含0·1至100毫克活性成分,較佳是〇 5至5〇亳克。 根據本發明化合物也可與一或多種其他用於所需洽療的活 性成分合併使用,例如與抗血栓劑,抗凝血劑,抗血小板 凝集劑,如敵匹達莫(dipyridamole),阿斯匹靈,替克勞皮 定(toclopidine),克勞匹道(clopid〇grel)* nb/nia·蛋白複 合物拮抗劑合併使用。 醫藥組合物係供給予哺乳動物,包括人,調配用以治療上 (请先聞讀背面之注意事項^^寫本頁} 裝· 訂·
-9- 本紙張尺度適用中國國家標隼(CNS )八4規格(210X297公釐) 550267 Α7 Β7 發明説明(7 經濟部中夬榡準局員工消費合作、社印製 述疾病。 這樣製得的醫藥組合物較佳 喝的溶液,糖衣β 形式,如可注射的或可 农叙,一般的錠或明膠膠囊。 是較佳醫藥形式。本發明 了/王射的/合硬 έ ^ 動脈粥樣硬化,腫瘤手術後觀察到 、二二丄己的、病毒或酶致活劑引起的高凝血可能性。 -般而言’本發明五糖可用於治療由凝血障礙所致 病。 劑量視病人年齡、體重及健康視況、疾病嚴重程度及给予 途徑在大範圍内變化。此劑量包括每天給予-或多個約0.5 毫克至約刪毫克,較佳是約1至約100毫克/天,較佳是約 0.5至、勺50毫克/天,例如約2 〇毫克/天,作肌肉内或皮下一 人、予或規則地間隔給予,或是每天經口給予约毫克至 約1000毫克的每日劑量。 自乂此等劍量可視血液分析所得結果就每一病人作調 整。皮下給予是較佳途徑。 所以’本發明主題也是醫藥組合物,其含有作爲活性成分 的一種上述化合物,視需要與其他活性成分合併。等組合 物可製成可供經消化道或非經腸給予。 於供經口、舌下、皮下、肌肉内、靜脈内、經皮、經黏 膜、局邵或直腸給予的本發明醫藥組合物中,活性成分可 以單位形式給予,與標準的醫藥支撑混合給予動物或人 類。適苴的給予單位形式包括經口形式,如經口懸浮液, 各液’顆粒及散,明膠膠囊及錠,舌下及頰給予的形式, (請先聞讀背面之注意事項寫本頁) 裝· >項\^^寫太
10 本紙張尺度適用中國國家標率(CNS ) A4規格(210X297公釐) 550267 A7 B7 經濟部中央標準局員工消費合作社印製 五、發明説明(3 ) 皮下肌肉内、靜脈内、鼻内或眼内給予的形式,及直腸 給予的形式。 在將固體、也合物製成錠劑形式時,是將主活性成分與醫藥 上可接受載體如明膠,澱粉,乳糖,硬脂酸鎂,滑石粉, 阿拉伯膠,爭處合。鍵劑上也可塗覆蔑糖或其他適宜的物 料,或者是T加以處理使具維持長期活性以持續釋出預先 決定量的活性成分。 明膠膠囊製劑是藉混合活性成分與稀釋劑並將所得混合物 裝入軟或硬明膠膠囊内製成。 可於水内分散的散或顆粒可含與分散劑或濕潤劑或懸浮劑 如聚乙晞吡咯酮以及甘味劑或矯味劑混合的活性成分。 作直腸給予時是用塞劑,塞劑是用結合劑製備,此類結合 劑如椰子油或聚乙二醇,可於直腸溫度熔化。 供非經腸、鼻内或眼内給予時,是使用含醫藥上相容的分 散劑及/或潤潤劑,例如丙二醇或丁二醇,的水性懸浮液, 等張生理鹽水溶液,或滅菌的的可注射的溶液。 供經黏膜給予時,活性成分可與促進劑如膽鹽,親水聚合 物如羥基丙基纖維素,羥基丙基甲基纖維素,羥基乙基2 維素,乙基纖維素,羧基甲基纖維素,糊精,聚乙埽吡咯 酮,果膠,澱粉,酪蛋白,丙締酸,丙埽酸酯及其共^ 物,乙烯基聚合物或共聚物,聚環氧乙烷聚合物,聚醚戋 其混合物調配。 活性成分也可調配成微膠囊形式,視需要使用一或多種支 撑或添加物。 -11 - (請先閱讀背面之注意事項寫本頁) 丨装· >項\^^寫太 訂
本紙張尺度適用中國國家標率(CNS ) A4規格(210X297公釐) 經濟部中央標準局員工消費合作社印製 550267 A7 B7__ 五、發明説明(9 ) 活性成分也可是與環糊糖的複合物的形式,例如以-,0 _ 或r -環糊精,2 -羥基丙基-環糊精或甲基—/5 -環糊精。 活性成分也可藉由含有此活性成分的氣球釋出,或藉由血 管内補充劑f I入血管内釋出。這樣不會影響活性成分的藥 理效果。 皮下給予是較佳的途徑。 下述方法,製備,及方案説明各種用以製備本發明五糖的 中間體的合成。 使用下述縮寫: TBDMS :第三-丁基二甲基矽烷基;Lev :菊芋糖基;Bn : 苄基;Bz :苯甲醯基;TLC :薄層色層分析;〇lm :三氯乙 醯亞胺基;LSIMS :液體第二離子質譜分析;ESIMS :電喷 離子化質譜分析;TMS :三甲基矽烷基;TSP :三曱基矽烷 基四氘丙酸鈉;If :三氟甲磺酸鹽;MS :分子篩;All :晞 丙基;PMB ··對-甲氧基苄基;SE :三甲基矽烷基乙。 Dowex®,Sephadex®,Chelex® 及 Toyopearl® 都是登記商 於下述方法,製備及實例中,關於醯亞胺酸基的催化偶 合,菊芋酯之裂解,硫基苷之催化偶合,皀化,對-甲氧基 苄基之甲基化及選擇性去保護,寡糖及多糖藉加氫分解苄 基酯或醚之去保護及硫酸化,酯之包化或硫酸化之一般工 序係使用下述一般方法及中間體完成。 本發明化合物是根據下述各製備合成。 -12- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) (請先閱讀背面之注意事項\^寫本頁) 裝·
550267 A7 B7 五、發明説明(1〇)
OAc
AC2Ppyridine A-1
OH
〇H
I 10· OMe t OH
'OH
HO (請先閱讀背面之注意事項再填寫本頁) IR-12P Ho 8{rp 6h A- φ。 ΟΛ 衮il %姊雜_ TBSO-
、1T
經濟部中央標準局員工消費合作社印製 TBi〇 — cx--llCHMgBr i。大
O THFOOCJO — 85。/0
-13- 本紙張尺度適用中國國家標隼(CNS ) Α4規格(210X297公釐) 550267 A7 B7 五、發明説明(11 ) 經濟部中央標準局員工消費合作社印製
OCDn
OAC
OAC 斗彿1 -(鏢一 12
OCDn
OCDn
oCDn ο X .7β·0-ν20·0 s /
oron
Me〇Na, Me〇H 200°3 h -T (請先閱讀背面之注意事項再填寫本頁) -14- 本紙張尺度適用中國國家標隼(CNS ) A4規格(210X 297公釐) 550267 A7 B7 五、發明説明(12:
12
oron 3) BnBr, KHC03, DMF . 75 %
1) 03οηοι2'786 2) Naclo2, ψί^τ 審·,tBuOH
TsCI, pyr. -▼2°oc, 3ΙΓ 80 % ?〇 OMe (請先閲讀背面之注意事項再填寫本頁) 85 % 20OC.2 h
Aco. pyr. 經濟部中央標準局員工消費合作社印製
OBn 1CJ1
13
oCDn 70 %
o’l M NaOH 70 % 〇Me 8°oc,3h
aq AC〇H 80 % -T 5 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) 經濟部中央標準局員工消費合作社印製 550267 A7 B7 五、發明説明(13)
製備I 6-0-第三-丁羞二甲基矽烷基」,2_〇-異亞丙基甲基 D-呋喃葡葡修(2) 將二醇1(10克,42.7毫莫耳)溶於無水二氣甲烷(1〇〇毫升) 内,加第三-丁基二甲基矽烷基氯(71克,47.3亳莫耳)及咪唑 (5.8克,85.3毫莫耳)。將此反應混合物於室溫攪拌。2小時 後,反應混合物用二氣甲烷稀釋,用水洗。有機相於硫酸 鎂上乾燥,農縮,殘餘物於二氧化矽膠上作色層分析純化 (1/9容積/容積:醋酸乙酯/環己烷),製得所需產物2(11.9克, 80%) ’爲糖漿形式。 [^ ]D -34〇C (c 1·9,CHC13) 〇 製備2 6-0-第三-丁基二甲基矽烷基dio—異亞丙基甲基_5· C-乙晞基-“ 呋喃葡葡糖(4) 將草醯氣(3.2毫升,36.8毫莫耳)及二甲基亞颯(5·2毫升, 73.4¾莫耳)於-78°C加於無水二氯甲烷(4〇毫升)内,將此混 合物攪拌30分鐘。然後加化合物2(6·4克,18 4毫莫耳),再 將混合物攪拌1小時。然後加三乙基胺(15·3毫升,11〇〇毫 莫耳),30分鐘後此混合物以二氯甲烷稀釋。以標準方法收 取,得5-碳糖(5-ul〇Se)化合物(3),直接用於下一反應。將 粗製酮3溶於無水四氫呋喃(1〇〇毫升)内,於〇。(:加1]^的溴化 乙晞基鎂於四氫呋喃内之溶液(28毫升,27·6毫莫耳)。卜】、 時後,將反應混合物稀釋,不用氯化銨,用水洗。有機相 方;鎂上乾燥,濃縮,殘餘物於二氧化碎膠上作色層分 -16- 本紙張尺度適用中國國家標隼(CNS ) A4規格(210X297公釐) (請先閲讀背面之注意事項再填寫本頁) 装- 4T» 550267 Α7 Β7 14 五、發明説明( 析純化(1/9容積/容積醋酸乙酯/環 衣匕;凡j,製传所需彦% 4(70%,4·8克),爲糖漿形式。 明 [а] D -40。。(e 1.3,CHCl3)。 分析計算:C,57.72,Η,9·15。實測·· c,57·7?,η 9 23。 製備3 5 l,2,4,6-四-Ο-乙酸基-3-0-甲基-5-C-乙樣美 γι a jl* μ l 布基-P-D-吡喃葡葡糖 (б) 將化合物4(3.5克,9·4毫升)溶於水(5〇毫升)内,其内加 IR-120樹脂(I克),此混合物於8(rc加熱6小時。濾出樹脂, 知滤過物丨辰度^此粗製產物5用醋酸肝(丨2毫升)及p比矣(i 3 毫升)乙醯化。用甲醇破壞多餘的醋酸酐,濃縮溶劑。殘餘 物用水及二氣甲烷萃取。有機相於硫酸鍰上乾燥,濃縮, 殘餘物於二氧化矽膠柱上作色層分析純化(3/2容積/容積醋 阪乙醋/ %己:) ’製传四醋酸鹽6,爲固體形式(75%,27 克),溶點=5 0 °C。 〇 ]D -84°C (c 1 .6,CHC13) 〇 分析計算·· C,52.47,H,6.19。實測:C,52.51,H,6· 19。 CI-MS ·· 406 (Μ + ΝΗ4),389(Μ + 1) 〇 製備4 經濟部中央標準局員工消費合作社印製 甲基2,3,6-三-Ο-爷基-4-0-(2,4,6-三-Ο-乙醯基-3-0-甲基-5-C-乙晞基-Θ-D-毗喃葡葡糖基)-“-D-吡喃葡糖甞(8) 將化合物6(1·6克,4·1毫莫耳)及化合物7(2·1克,4.5毫莫 耳)(P.J. Garegg and Η. Hultberg,Carbohydr. Res· 1981,93, CIO)溶於無水二氯甲烷(50毫升)内,加内子篩(4·0克)。此 -17- 本紙張尺度適用中國國家標準(CNS ) Α4規格(210Χ297公釐) 550267 A7 B7 五、發明説明( -15 反應/昆合物方+ ▲溫攪拌1小時’然後於_78°C加TMS OTf(0.95 毫升,5·2毫漠耳)。然後任此反應混合物緩慢升至室溫。2 小時時,反應混合物用三乙基胺中和,用矽藻土過濾,濾 過物用水洗。有機相硫酸鎂上乾燥,濃縮,殘餘物於二氧 化秒膠上作色層分析純化(4 /1容積/容積醋酸乙酉旨/環己 燒)’製得所需化合物8(2.77克,85%),爲固體形式,熔點 = 4 7〇C 〇 請 先 閱 讀 背 面 之 注 經濟部中夹槔率扃貝少消費含作社印繁 〇]D -36C (c 0.6,CHC13)。 分析計算:C,65.14,H,6.61。實測:C,65.09,H,6.70。 製備5 甲基2,3,6-0-三-〇-芊基-4-0-(4,6-0-異亞丙基-3-0-甲基-5-C-乙晞基·々-D-吡喃葡糖基吡喃葡糖甞(10) 將化合物8(2.7克,3.4毫莫耳)溶於甲醇(40毫升)内。於〇 °C加鈉(催化齊,』),此混合物於室溫攪拌3小時。濃縮溶劑, 將殘餘物9溶於無水丙酮(40亳升)内,加2,2-二甲氧基丙烷 (2毫升)及對-甲苯績酸(催化劑)。此反應混合物於室溫揽拌 過夜。蒸發去溶劑,將殘餘物溶於氯仿内,用水洗。有機 相於硫酸鎂上乾燥,濃縮,殘餘物於二氧化矽膠柱上作色 層分析純化(1/1容積/容積醋酸乙酯/環己烷),製得4*,6’-異 亞丙基-0-衍生物1〇(1.7克,70%),爲固體形式,熔點= 55°0。 [汉]d +13〇C (c 〇·8,CHC13)。 分析計算:C,67.97,H,7.13。實測·· C,67.87,H,7.16。 CI-MS ·· 707 (M + 1),724(M + NH4)。 製備6 18- 張尺度適用中國國家標準(CNsi^4規格(210X297公釐)
f 550267 16 經濟部中央標準局員工消費合作社印製 A7 B7 五、發明説明( 甲基2,3,6_三-O-爷基-4-0-(4,6-0-異亞丙基-3-0-甲基-5-C- 乙烯基毗喃葡葡糖基)-a-D-吡喃葡糖菩(12) 將草醯氯(0.35毫升,4.0毫莫耳)及無水DMSO(0.57毫升, 8.0毫莫耳)命無水二氯甲垸(1〇亳升)内於攪拌3〇分 鐘。於此溶液中加入在無水二氯甲烷(丨〇毫升)中的化合物 10 (1·4克,2· 0毫莫耳),繼續再攪拌45分鐘。反應混合物用 無水三乙基胺(1.7毫升’ 12.0毫莫耳)中和,然後用二氯甲燒 稀釋。經由私洗後’有機相於硫酸鎮上乾燥,濃縮,殘餘 物1 1直接用於下一反應,不必純化。將酮1 1溶於無水四氫 呋喃(1 5毫升)内,於-78°C加四氫氟喃内的1 ν的超氫化物 (supar hydride)溶液(4毫升,4.0毫莫耳)。此反應混合物於 室溫攪拌1小時,加5 %氫氧化鈉(2毫升)及過氧化氫(1亳 升)。蒸發去溶劑,將殘餘物溶於醋酸乙酯内,用水洗。有 機相於硫酸鎂上乾燥,濃縮,殘餘物作色層分析純化(2/1容 積/容積醋酸乙酯/環己烷),製得化合物12(1.0克,70%)。 [叫D -ire (C 0·5,CHC13) 〇 CI-MS : 724 (Μ + 18),707(M + 1) 〇 製備7 甲基2,3,6-三-Ο-芊基-4-0-(2-0-乙醯基-3-0-甲基-5-C-乙烯 基吡喃甘露糖基吡喃葡糖甞(14) 將化合物21(940毫克,1.3毫莫耳)溶於吡啶(3毫升)内, 加醋酸酐(0·3毫升)。此反應混合物於室溫攪拌3小時。濃縮 超量的吡啶及醋酸酐,殘餘物1 3直接用於異亞丙基的去保 護,用80%醋酸(5毫升),於60°C進行2小時。蒸發去超量 -19- 本紙張尺度適用中國國家標準(CNS ) A4規格(2l〇X297公釐)
550267 A7 B7 五、發明説明( 17 經濟部中央標準局員工消費合作社印繁 的醋酸,殘餘r物於二氧化矽膠柱上作色層分析純化(4 /丨容積 /谷積醋fe乙酉旨/環己烷),製得二醇14(66〇毫克,7〇%),爲 固體形式,象點= 53°C。 |> ]D -10〇C (c 0.8,CHC13) 〇 CI-MS : 709 (Μ + 1),726(M + 18) 〇製備8 甲基2,3,6-二-〇-芊基-4-0-(2-0-乙醯基-3_〇_甲基-6-〇_甲苯 磺醞基-5-C-乙晞基·/? -D-吡喃甘露糖基從_D-吡喃葡糖铱 (15) 將化合物14(600毫克,〇·9亳莫耳)溶於吡啶(3毫升)内, 加甲苯磺醯氯(240毫克,1.3毫莫耳)。此反應混合物於室溫 攪拌3小時。蒸發去溶劑,殘餘物用氯仿稀釋,用水洗。有 機相於硫鉍鎂上乾燥,濃縮,殘餘物於二氧化矽膠柱上作 色層分析純化(1/1容積/容積之醋酸乙酯/環己烷),製得甲 苯磺醯基化合物15(297毫克,80%),爲糖漿形式。[a]D -26〇C (c 0.8,CHC13)。 製備9 甲基2,3,6-二-〇_芊基_4-〇-(2-〇-脱水甲基。/-乙烯基· -D-响喃甘露糖基喃葡糖苷(16) 將化合物15(550毫克,〇·6毫莫耳)溶於乙醇(3毫升)内, 然後加0· 1N乙醇氫氧化鈉溶液(5毫升)。此反應混合物於7〇〇c 加為3小時’然後用ir_ 12〇樹脂(h+形)中和,用碎藻土過 濾。濃縮後,殘餘物於二氧化矽膠柱上作色層分析純化(1/1 谷積/容積醋酸乙酯/環己烷),製得化合物16(292毫克, 20- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) (請先閱讀背面之注意事 裝-- :寫本頁)
550267 A7 B7 五、發明説明(18 ) 經 濟 部 中 央 隼 局 員 X 消 費 合 作 社 印 製 70%),爲糖聚形式。 [a ]D +13°C (c 0.5,CHC13)。 CI-MS : 666 (M + 18) 〇 製備10 甲基2,3,6-二爷基-4-0-(苄基-3-0-甲基_2_〇-5-C-亞甲基· α-L-吡喃艾桂糖醛酸酯)^_D_吡喃葡糖甞(17) 將化合物16(260¾克,〇 4毫莫耳)溶於二氣甲烷(2〇毫升) 内,此溶液於-78°C攪拌,然後進入臭氣30秒。此溶液變灰 黃色。於此容液内加二甲基硫,此反應混合物用水洗。有 機相於硫酸鎂上乾燥,濃縮,直接進行下一反應,不必純 化。將此粗製酸溶於第三·丁醇(1 6毫升)内,加2-甲基丁 晞(5毫升)及水(1 6毫升)。然後於此混合物内相繼加 NaH2P〇4(700毫克)及NaCi〇2(7〇〇毫克)。將此懸浮液於室溫 強列授拌過夜’用水稀釋,用醋酸乙酯萃取。有機相於硫 版鎂上乾燥’濃縮’直接進行下一反應。將粗製酸溶於二 甲基甲醯胺(2 5毫升)内,然後加碘化四丁基銨(〇7克,2.0 愛莫耳),碳酸氫鉀(0.25克,2.5毫莫耳)及苄基溴(0.250毫 升’ 2· 1毫莫耳)。此反應混合物於室溫攪拌5小時。此反應 混合物用水及二乙醚萃取。醚相於硫酸鎂乾燥,濃縮,殘 餘物於二氧化石夕膠柱上作色層分析純化(2 /;1容積/容積醋酸 乙酯/環己烷),製得衍生物17(236克,80%),爲糖漿形 式。CI-MS : 774(Μ+18)。 請 · 先-閲 讀 背押
訂 •t -21 - 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) 550267 A7 B7 五、發明説明(19 ) 方案2 :醯亞胺酸基DEF(l8)與GH(17)之縮合,去保護與硫 酸化。 ^
批衣------訂---- (請先閱讀背面之注意事項寫本頁)
線 經濟部中央標準局員工消費合作社印製
本紙張尺度適用中國國家標隼(CNS ) Α4規格(210Χ297公釐) 550267 A7 ____B7_ 五、發明説明(20 ) 製備11 甲基0-(6-0-乙醯基·2,3,4-三-〇-甲基-比喃葡糖基)_(ι —4)-〇-(苄基2,3-二-〇-甲基-/? -Ο-p比喃葡糖酸酸酯)_(1->4)_ (^-^乂-一…-乙醯基^…-芊基-“-^-说喃葡糖基)·。—^)·^-(2,6-脱水-5_(!:-苄基氧基-羰基_3-〇-甲基_/?_〇-吡喃甘露糖 基)-(l —4)-2,3,6-三-0-爷基比喃葡糖:y:(19)。 將驢亞胺敗基18(\^11(161*1^」(16116{&1.,&681;1',91:11£111··
Carbohydr. Symp· Utrecht,July 6-11,1997; A74, p 154)(81 毫 克’ 78.2微莫耳)’接受體17(65毫克,86.0微莫耳)及細分子 篩(70¾克’ 4又)於1/2(容積/容積)二氣甲烷/二乙陡混合物 (2.4毫升)内在惰性氣體下攪拌。 將此反應混合物攪拌30分鐘,然後加NaHC03至中和點。 過濾並濃縮後,殘餘物Sephadex®LH20凝膠柱上純化(1/1 容積/容積二氯甲烷/乙醇)純化,然後於二氧化矽膠柱上純 化(in容積/容積醋酸乙酯/環己烷),製得化合物19(86毫 克,67%) 〇 [a]D +66〇C (c 1.0,CH2CH2) 〇 4 NMR如表1所示。 製備12 經濟部中央標準局員工消費合作社印製 甲基 0-(2,3,4-二-0甲基-“ _D-p比喃葡糖基)-(1 ~~>4)-〇-(2,3-二-0-甲基· y5 -Ο-ρ比喃葡糖酸酸)_(ι _>4)·0-( a -D-p比喃葡♦♦ 基)-(1~>4)-0-(2,6-脱水-5-(%羧壹-3-0-甲基-/?-0-?比喃甘露 糖基)-(1 —4)-沈-D-吡喃葡糖茹(2〇) 〇 根據 Μ· Petitou and C.A.A· van Boeckel,Progress in the -23- 本紙張尺度適用中國國家標準(CNS ) A4規格(2⑴x297公釐) ~~~ 550267 A7 B7 五、發明説明( 21
Chemistry of Organic Natural Products, Published by W. Herz et al. Vienna,Springer-Verlag,New York,1992, 143-210 0 將化合物19(49毫克,30.0毫莫耳)於醋酸(3毫升)内之溶 液在氫氣(3.5 MPa)下於40°C在有5 %鈀/碳(73毫克,35 b)之 存在下攪拌1 2小時。此混合物用矽藻土過濾,濃縮,與水 共蒸餾(4 X 5毫升)。將殘餘物溶於iM NaOH水溶液(3毫升) 内’於5 5 °C加熱3小時。將此溶液冷卻,用Sephadex® 625 F柱(170亳升)過濾,用水洗滌。將含化合物2〇的各部分用 Dowex H+樹腊過濾。將洗離物濃縮,製得化合物2〇(25毫 克,86%)〇 [沈]D +105°C (c 1.0,H20)。 W NMR如表1所示。表1 (請先閱讀背面之注意事項寫本頁) 裝· .項寫太 訂 部 中 央 h 準 局 員 工 消 費 合 作 社 印 製 經 化合物 單位 H-l H-2 H-3 H-4 H-5 Η-6 Η-6, Jl-2 19(CDC13) D 5.50 3.11 3.37 3.03 3.43 4.28 4.22 3.7 E 4.14 2.93 3.31 3.92 3.83 - - 〜9 F 4.98 3.45 5.41 3.63 3.94 4.58 4.19 3.6 G 5.18 3.83 3.12 4.12 - 4.10 3.98 〜1 Η 4.58 3.51 4.01 3.78 3.80 3.83 3.61 3.6 20(D2O) D 5.50 3.33 3.49 3.30 3.50 3.74 3.74 3·9 E 4.62 3.26 3.58 3.90 4.04 - - 7.9 F 5.13 3.58 3.76 3.61 3.70 至 3.90 4.1 G 5.23 4.35 3.71 4.20 - 4.25 4.10 〜1 H 4.82 3.64 3.84 3.73 3·70 至 3·90 3.7
-24- 太紙復尺唐適用中國國家標準·( CNS ) A4規格(210X 297公釐) 550267 經濟部中央標準局員工消費合作社印製 A7 B7 五、發明説明(22 ) 方案3 :供應者EF之製備,二糖29
-25- 本紙張尺度適用中國國家標隼(CNS ) A4規格(210X 297公釐) 550267 A7 B7 五、發明説明(23 ) 製備1 3 甲基0-(4,6-O-異亞丙基-2,3-二-〇-甲基-5-0乙晞基-/5 -D-吡 喃葡糖基Ml —4)-2,3,6-三-0-苄基-a -D-吡喃葡糖苷(2 2) 將氫化鈉(0.31克,13.0毫莫耳)於〇°C加於甲基〇-(4,6-0-異 亞丙基-3-0-甲基-5-C·乙晞基-/? -D·峨喃葡糖基)-(1— 4)- 2.3.6- 三-0-苄基吡喃葡糖:y:(i〇)(6.11克,8.65毫莫耳) 及甲基碘(0.8 0毫升,13·0毫莫耳)於n,N-二甲基甲醯胺(9.00 亳升)内之溶液中。將此混合物攪拌2小時(TLC),加甲醇, 將反應混合物倒入水内。此混合物用醋酸乙酯萃取,萃取 物用水洗,乾燥,濃縮。殘餘物於二氧化矽膠柱上純化(3 /2 容積/容積環己烷/二乙醚),製得22(5.92克,88%)。 TLC ·· Rf=0.28(3.2(容積/容積)環己烷/二乙醚) 製備14 甲基0-(4,6-0-異亞丙基-2,3-二-〇-甲基-5-C-乙基-D-吡喃 葡糖基)-(l —4)-2,3,6-三-0-爷基-α-D-p比喃葡糖:y:(23) 將氧化鉑(160毫克)加於22(5· 80克,8.04毫莫耳)於醋酸乙 酯(400毫升)内之溶液中。引入氫氣。任混合物攪拌4 〇分鐘 (TLC),過濾,蒸發,製得32。TLC : Rf=0.60(4/1(容積/容積) 甲苯/醋酸乙酯)。 經濟部中央標準局員工消費合作社印象 (請先閱讀背面之注意事項再填寫本頁) 製備15 甲基0-(2,3-二-0-甲基- 5-C -乙基-D-p比喃葡糖基)-(1~~>4)_ 2.3.6- 三-〇-苄基-以-〇-吡喃葡糖苷(24) 將粗製化合物23溶於70%醋酸(60亳升)内,於80°C攪拌2 小時。將此混合物眞空濃縮,並與甲苯共蒸發,製得24。 -26- 本紙張尺度適用中國國家標擎(CNS ) A4規格(210X297公釐) 550267 A7 _B7 五、發明説明(24 ) TLC : Rf=0.5 2(4/1(容積/谷積)二氯甲燒/甲醇)。 製備16 甲基0-(爷基)2,3-—-0-甲基- 5-C-乙基-D-p比喃葡糖酸酸 酿)-(l —4)-2,3,6-二-0-+ 基- α-D-p比喃葡糖芬(25) 將2,2,6,6-四甲基-1·六氫吡啶基氧基(17·5毫克),碳酸氫 納溶液(17·5囊升),/臭化钾(87¾克)及氣化四丁基铵(in;毫 克)加於化合物24(5.75毫克)於四氫呋喃(28毫升)内之溶液 中。將此混合物冷至0°C,用15分鐘時間加入飽和氯化鈉溶 (1 7毫升),飽和碳酸氫鈉溶液(8·70亳升)及次氯酸鈉(1.3 Μ,20毫升)之混合物。攪拌1小時後,此混合物用水稀釋, 用一鼠甲紀萃取(二次)。有機相用氯化鋼水溶液洗,於硫 酸鎂上乾燥,過濾,蒸發至乾,得粗製酸衍生物。 將此酸衍生物在氮氣下溶於Ν,Ν-二甲基甲酿胺(1〇7毫升) 内。加碳酸卿鉀(4· 10克)及芊基溴(9.70亳升),將此混合物 攪拌1 6小時。加促酸乙酯及水,萃取後,將有機相濃縮。 於二氧化矽勝柱上作色層分析純化,製得3·81克化合物 25(60%產出率,以化合物23計)。 [a ]D +24°C (c = 0.15,二氯甲燒)。 製備17 經濟部中央標準局員工消費合作社印裂 (請先閱讀背面之注意事項再填寫本頁) 甲基0-(苄基-5-C-乙基-4-0-菊芋基-2,3-二_〇-甲基峨 喃葡糖醛酸酉旨)-(1~>4)-2,3,6-三-〇-爷基-a -D-外(:喃葡糖嘗(26) 將化合物25(3.51克,4.46毫莫耳)溶於無水二啰烷(45毫升) 内。加菊芋酸(1.00克,8.93毫莫耳),1-(3-二甲基胺基丙 基)-3-乙基碳 匕二亞胺鹽酸鹽(1·7〇克,8·93毫莫耳)及4·二 -27- 本紙張尺度適用中國國家標箏(CNS ) Α4規格(210Χ297公釐) 550267 經濟部中央標準局員工消費合作社印製 A7 _____ B7_____ 五、發明説明(25 ) 甲基胺基吡途(0.11克,8.93亳莫耳)。任此混合物攪拌16小 時’用醋酸乙醋萃取,萃取物相繼用5 %硫酸氫鉀水溶液, 水,及飽和碳酸氫鈉水溶液及水洗,乾燥,濃縮。殘餘物 於二氧化矽膠柱上作色層分析純化(2/1然後3/2(容積/容積) 環己烷/醋酸乙酯),製得純26(3.64克,85%)。 [a ]d +26°C (c=0.9,二氯甲烷)。 製備18 〇-(苄基5-C-乙基-4-0-菊芋糖基_2,3·二-0-甲基-/? -D-吡喃 葡糖酸酸酯)-(1~>4)-1,3,6-三-〇-乙醯基-2-0-苄基-〇-吡喃葡 糖芸(27) 將化合物26(3.35克,3.78亳莫耳)溶於醋酸酐(22毫升) 内。將此各液_冷至-20C ’加22毫升冷的硫酸於醋酸(1毫升 硫酸於1 0毫升醋酸酐内)内之溶液。此混合物用醋酸乙酯稀 釋,用飽和碳酸氫鈉水溶液及水洗,用水洗,乾燥,濃 縮。殘餘物於二氧化矽膠柱上作色層分析純化(1/1(容積/容 積)環己烷/醋酸乙酯)得到化合物27(2.20克,65.5%)。TLC : Rf=0.24 ’(1/1,(容積/容積)環己烷/乙酸乙酯)。 製備19 〇-(苄基5-C-乙基-4-0·菊芋糖基_2,3_二-0-甲基-D-吡喃 葡糖酸酸酯)-(1 — 4)-3,6-二-〇-乙醯基-2-0-苄基-〇4喃葡糖 甞(28) 將苄基胺(1 1亳升,1〇1·4毫莫耳)加於化合物27(2.18克, 2.67毫莫耳)於四氫氟喃(5〇毫升)内的溶液中。任此混合物 攪拌4小時。用醋酸乙酯萃取,用1 μ鹽酸水溶液(102毫升) 洗’用水洗,乾燥,濃縮。殘餘物於二氧化矽膠柱上作色 -28 - 本紙張尺度適用中國國家標準(CNS ) Α4規格(210X 297公釐) (請先閱讀背面之注意事項再填寫本頁) -. 訂
550267 A7 B7 五、發明説明(26 ) 層析純化(1/ 1 (容積/容積)甲苯/醋酸乙酯),製得化合物 28(1.33 克,65%)混合物(^//5=^0/50)。 TLC : Rf=0.22(l/1(容積/容積)甲苯/醋酸乙酯)。 製備20 〇-(苄基5-C-乙基-4-0-菊芋糖基_2,3_二-〇-甲基--D-吡喃 葡糖醛酸酯)-(l —4)-3,6-二-〇-乙醯基-2-0-苄基-D-吡喃葡糖 基三氣乙醯胺酸酯(29) 將化合物28(1.32克,1.71毫莫耳)溶於二氯甲烷(3 4毫升) 内,在氬氣下加三氯乙腈(0.87毫升,8.50毫莫耳)及碳酸铯 (0.90克’ 2·73毫莫耳)。任此混合物授掉2小時(TLC),過 慮。殘餘物於一氧化珍膠柱上作色層分析純化(3 /2 (容積/容 積)環己烷/醋酸乙酯),製得化合物29(1·2〇克,77%)混合物 (α//?=85/15) 〇 (請先閲讀背面之注意事項再填寫本頁) 、tr 經濟部中央標準局員工消費合作社印策 TLC : Rf=〇.36(l/2(容積/容積)環己烷/醋酸乙酯)。 方案4 :接受體四糖3 1之製備
本紙張尺度適用中國國家標準(CNS ) Α4規格(210X297公釐) 經濟部中央標準局員工消費合作社印製 550267 A7 __________B7____ 五、發明説明(27 ) 製備2 1 甲基0-(节基5-C-乙基-4_〇_菊芋糖基-2,3-二-〇-甲基-η 叶匕喃葡糖酸敗酉旨)-(1 4)-0-(3,6·二-Ο-乙醯基-2-0-爷基-沈- D-说喃葡基)-(1—4)-〇-(2,6-脱水-5-C-芊基氧基羰基-3-0-甲 基-y5 -D-p比喃甘露糖基)-(1^4)-2,3,6-三-0-芊基-a -D-p比喃葡 糖苷(3 0) 將第三丁二甲基矽烷基三氟甲磺酸鹽於二氯甲虎内之溶 液(1Μ ’ 0·19亳升)在氬氣下於-2〇〇c加於醯亞胺酸g旨29(119 克,1.29毫莫耳)及甲基2,3,6-三-〇-爷基-4-(苄基-3-0-甲基-2-0-5-C-亞甲基-α-L-峨喃艾桂糖醛酸酯吡喃葡糖:y: 17(1.02克,1·35毫莫耳)於甲苯(4〇毫升)内之有4人分子篩 (1.93克)溶液中。30分鐘後(TLC),再加第三-丁基二甲基矽 燒基三氟甲績酸鹽於二氣甲烷内之溶液(1]νι,〇·ΐ9毫升)。 3 0分鐘後(TLC),加固體碳酸氫鈉。將溶液過濾,用水洗, 乾燥並蒸發至乾。殘餘物於Sephadex® LH20上作柱色層分 析’再於二氧化石夕上作色層分析純化(2 /1 (容積/容積)甲苯/ 醋酸乙酯),製得純四糖30ι(1·14克,58%)。 [a ]D +47 (c=0.21 ’ 二氣甲燒)。 製備22 甲基0-(卞基5-C-乙基- 2,3 -二-0 -甲基-/J -D-p比喃葡糖酸酸 酉旨)-(1—4)_〇_(3,6-二-0-乙醯基-2-0苄基比喃葡基)_(1 —4)_〇-(2,6-脱水-5-(!!-:¥:基氧基魏基-3-0-甲基-^5-〇-峨喃甘 露糖基)-(l —4)-2,3,6-三·0·爷基-α-D-p比喃葡糖:y:(3i) 將化合物30( 1 · 13克,0.75毫莫耳)溶於2/1(容積/容積)乙醇 /甲苯混合物(150毫升)内,加醋酸肼(0.35克,3 73毫莫 耳)。任此混合物攪拌1小時(TLC),濃縮。殘餘物於二氧化 矽柱上作色層分析純化(3/2(容積/容積)甲苯/醋酸乙醋 -30- ^氏張尺度適用中國國家標準(CNS ) A4規格(210父297公釐了 (請先閱讀背面之注意事項再填寫本頁)
、?! 550267 A7 B7 五、發明説明(28 ) 製得 31(0.816 克,83%)。 I>]d+35 (c=1.01,二氯甲烷)。 方案5 :四糖EFGH(31)與糖基供應者〇(32)之偶合去保護與 硫酸化 CQr\
36 經濟部中央標準局員工消費合作社印製 (請先閲讀背面之注意事項再填寫本頁) -31 - 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) 550267 Α7 Β7 29 五、發明説明( 製備23 甲基0-(6-0-乙醯基-2,3,4_三-0-甲基-/?-0-吡喃葡糖基)-(1 —4)-0-(苄基 5-C-乙基-2,3·二-Ο-甲基-/? -D-吡喃葡糖醛酸 酯)-(1~>4)-0-(3,6-二-0-乙醯基-2-0-芊基-“-0-吡喃葡糖 基)-(1 — 4)-〇-(2,6-脱水-5-(:-苄基氧基羰基-3-〇-甲基-0-〇-吡喃甘露糖基)-(1—4)-2,3,6-三-0-苄基-以-0-吡喃葡糖甞 (33) 將6-0-乙醯基·2,3,4-三-Ο-甲基-D-吡喃葡糖三氯乙醯胺酸 鹽 32(34.7¾ 克,0.0245 毫莫耳)(Ρ. Westerduin,et al·,BioOrg. Med· Chem·,1 994, 2, 1267)及糖基接受體3 1(80毫克,0.056 愛莫耳)根據製備2 1處理。此化合物於Sephadex® LH-20上 作管柱色層分析(1/1(容積/容積)二異丙基醚/醋酸乙酉旨)且隨 後在矽化物管柱上層析(3/2(容積/容積)二異丙基醚/醋酸乙 酯),製得衍主物33(54.6毫克,58%)。 [a ]D +55 (c=l,二氯甲燒)。 製備24 經濟部中央標準局員工消費合作社印製 甲基0-(6-0-乙驢基-2,3,4-三-0-甲基-α-D-p比喃葡糖基)_(ι ~>4)-0-(5-C-乙基-2,3-二-0-甲基- 比喃葡糖酸酸酉旨 4)-〇-(3,6-二-〇-乙醯基1-〇-说喃葡糖基)-(14 4)-0-(2,6-脱 水_5_C-叛基- 3-0-甲基-卢-D-p比喃甘露糖基)_ (1 a -D-p比 喃葡糖甞(34) 將化合物33(40毫克,0.024毫莫耳)於醋酸(2亳升)内之溶 液在氫氣下及有10%免/碳(8 0毫克)之存在下攪拌1 6小時, 過濾。將濾過物濃縮,製得化合物3 4。 製備2 5 -32- 本紙張尺度適用中國國家標率(CNS ) Α4規格(210x297公釐) 550267 A7 B7 五、發明説明(31 ) [“ ]D +49〇C (c=0.63,H20) 所得1HNMR*n表2所示。 表2 化合物 2l(D2〇) 單位 Η·1 Η-2 Η-3 Η·4 Η-5 Η-6 Η-6,
Jl-2 (Ηζ) 請 先 閱
D 5.46 3.32 3.55 3.34 3.87 4.28 4.12 3.9
E 4.66 3.26 3.53 3.89 3.73 7.9
F 5.50 4.36 4.81 4.00 4.17 4.49 4.41 3.7
装
G 5.49 4.41 3.73 4.17 4.24 4.09 Η 5.16 4.36 4.52 4.01 4.08 4.41 4.30 3.7 t 經濟部中央標準局員工消費合作社印製 實例2 甲基0-(2,3,4-三甲基- 6-0-續基-α-D-p比喃葡糖基)-(1 — 4)-0-(5-C-乙基-2,3-二-〇-甲基-卢-D-吡喃葡糖基-糖醛酸)-(1 4)-〇-(2,3,6 -二-〇·橫基-以-〇-?比喃葡糖基)-(1 ~^4)-0-(2,6-脱水-5-C-羧基-3-0-甲基-A -D-吡喃甘露糖基)-(1~>4)-2,3,6-二-〇-橫基-α-D-p比喃葡糖嘗,鋼鹽(36) 將三乙基銨/三氧化化硫複合物(9 1毫克)加於粗製化合物 35於二甲基甲醯胺(13毫升)内之溶液中。於55°c過2〇小 時’將此溶液置於Sephadex® G-25(2 X38公分)柱頂端,用 〇·2Μ氣化鈉洗離。將含產物部分濃縮,用同一柱以水洗 離。/東乾後製得化合物3 6 (21 · 9毫克,5 2 %,由化合物3 3計算)。 所得1H NMR如表3所示。 -34- 本紙張尺度適用中國國家標準(CNS ) A4規格(2!〇><297公釐) 訂 線 550267 A7 B7 五、發明説明(32 ) 表3 Η-1 (Ji-2 HZ) H-2 H-3 H-4 H-5 H-6 H-61 其他 D 5.43 (3.9) 3.28 3.52 3.30 4.02 4.27 4.14 Ε 4.68 (8.1) 3.27 3.60 3.98 2.041/1.80 ·· ch2ch3 09.4 : CH2CH3 F 5.50 (3.7) 4.35 4.50 3.84 4.07 4.61 4.30 G 5.47 (l.l) 4.39 3.72 4.16 - 4.23 4.08 Η 5.16 (3.7) 4.36 4.81 4.00 4.17 4.50 4.39 以如上實例1及2方法,製得下述實例3至6之化合物37至 4 0。所传此辛化合物的4 NMR讀與其如下所示構形一致。 實例3 J—>J----批衣-- (請先閱讀背面之注意事項再填寫本頁)
、1T 甲基0-(2,3,4 -二-0-甲基- 6-0-續基-α-D-p比喃葡择基)(1 — 4)_〇-(2,3-二-0_甲基-y5 _D-吡喃葡糖基-糖醛酸)·〇 (2,3,6-三-0-礙基-從-D-p比喃葡糖基)-(1~>4)-〇-(2,6_ 脱水 _5-C-羧基-3-0-甲基吡喃甘露糖基)-(1^4)-2-0-續基_3 6- 二-0-甲基吡喃葡糖甞,鈉鹽(37) [泛]d+51〇C (c=0.48,水)〇
.'線 經濟部中央標準局員工消費合作社印製
本紙張尺度適用中國國家標隼(CNS ) Α4規格(210X297公釐) 550267 Α7 Β7 五 發明説明( 33 實例4 甲基0_( 2,3,4-三-〇-甲基& # 3_二_0胃甲其Ρ · _〇-崤基WD·"比喃葡萄糖基)-( )…(,一 土乂 比喃葡糖基-糖醛酸 (2,3,6·三-Ο-續基 a _D-吡喃茴祕苴、^ ( ) 久土 _吡喃甘露糖基)-(1 —4)-2,3-二-〇-磺;| |〇_甲基比喃葡萄糖菩,鋼鹽(Μ)[a ]D +57〇C (ο=〇·28,水)。
實例5 甲基〇_(2,3,j· 一-0_甲基_6_〇_磺基-“_D_吡喃葡萄糖基)_〇 -~>4)_0-(2,3 _0-甲基-々_〇_峨喃葡糖基·糖醛酸 (2,3,6-二-0-石頁基 a _D-吡喃葡糖基)_〇44)-0-(2,6-脱水_5_ C-羧基-3·0-甲基-y5_D-吡喃甘露糖基”(丨―4)^,6·二_〇_磺基 -3-0甲基- D-p比喃葡萄糖省:,鈉鹽(39) [a]D+53〇C (e=0.3,水)。 (請先閱讀背面之注意事項再填寫本頁) 訂 經濟部中央標準局員工消費合作社印製
實例6 曱基0_(2,3,4·三-0·甲基_6_〇_磺基-a_D4喃葡萄糖基)_(][ ->4)-0-(2,3·二 _0甲基-yS _d_p比喃葡糖基 _ 糖酸酸)-(i —4)-0-(2,3,6-三0-續基 a -D-吡喃葡糖基)·(ΐ44)-〇-(2,7-脱水-5-C-羧基·6_脱氧-3-0-甲基-D-七吡喃甘露糖基)-(1 — 4)- -36- 本紙張^1適用中國國家樣率(〔奶)八4規格(210'乂297公釐) 550267 A7 B7 五、發明説明( 34 2,3,6-二-〇-續'基-<^-〇-'?比喃葡萄糖菩,鋼鹽(40) [a]D +49°C (c=0.25,水)。
Me〇Me〇^ ,01^¾6°
(請先閱讀背面之注意事項再填寫本頁)
訂 經濟部中央標準局員工消費合作社印製 -37- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) 修正 ΎΓ 私年月 申請曰期 X?. l η 案 號 8Slo 〇7 1 1 類 别 補充 Α4 C4 (以上各攔由本局塡註) —中文說明書修正頁(9〇$ 奋明~I ;----- 渐^專利説明書 中 文 發明 娜 名稱 英 文 新穎五糖,其製法及包含彼等之醫藥組合物 PR0CESSES FOR AND pharmaceutical compc CONTAINING THEM1' 姓 名 國 籍 皮堤淘瑪萊斯 法國 裝 發明 人 住、居沂 法國巴黎市喬瓦拉特路65號 姓 名 (名稱〉 法商沙諾費-辛芷拉保公司 經濟部智慧財產局員工消費合作社印製 三、申請人 線 國 籍 住、居所· (事務所) 代表& 姓 名 法國 法國巴黎市第174大道 伊莉莎貝絲梭特-萊麥特 本紙張又度適用中國國家標伞(CNS) A4規格(2i0 X 297 乂釐) 550267 A7 B7 第088100711號4利申請案 中文說明書替換頁(92年2月) 五、發明説明( 甲基0-(2,3,小三-0-甲基-α-D-吡喃葡糖基)-(l — 4)-0-(5-C-乙基_2,3 -二- Ο-甲基-冷-D-p比喃葡糖酸酸)-(i—>4)-0-(a-D-p比 喃葡糖基)-(1—4)-0-(2,6-脫水-5-(%致基-3-0-甲基-/3-0-叶匕 喃甘露糖基)-(l — 4)-a-D-吡喃葡糖:y:(3 5) 將5 Μ氫氧化鋼水溶液(2 16微升)加於粗製化合物3 4於甲醇 (866微升)内之溶液中。25小時後,引入水,此反應混合物 用86卩1^(16父@0-25凝膠柱(2\38公分)過濾,用水洗離。將 洗離物濃縮,用Dowex® 50 Η+柱(2毫升)過濾,凍乾。此 時,用1Η NM檢查所有已除去的保護基。 實例1 甲基0-(2,3,4-三-0-甲基-6-0-確基-(^-0-叶!:喃葡糖基)-(1 — 4)_0-(2,3_ 二-Ο-甲基-/3 -D-吡喃葡糖基-糖醛酸)-(1 — 4)-0-(2,3,4-三_〇-續基-“-0-吡喃葡糖基)_(1 — 4)-0-(2,6-脫水-5-C -幾基-3-0-1^基- /5-D-p比喃甘露糖基)-(l — 4)-2,3,6 -三-0-續 基-a -D-吡喃葡糖甞,鈉鹽(2 1 )
Ed· Emgl·,1993, 32, 1671-1690。 將化合物20 (20毫克,20.7微莫耳)及三乙基胺/三氧化硫複 合物(164毫克,0.90微莫耳)於二甲基甲醯胺(2毫升)内之溶 液於55°C在暗處加熱1 8小時3 0分鐘。將反應混合物冷至室 溫,然後用0·2Μ NaCl水溶液稀釋。然後將此溶液置於 Sephadex®G25F(170毫升)頂端,用〇.2MNaa水溶液洗滌。 將含五糖部分濃縮,用同一柱以水洗離。凍乾後製得化合 物 2 1(30.5毫克,85%)。 -33 本紙張尺度適用中國國家標準(CNS) A4規格(210 X 297公釐)
Claims (1)
- 裝550267訂 550267 A8 B8 C8 D8 六、申請專利範圍 葡糖菩,鋼鹽。 •甲基0-(2,3,4-三-0-甲基-6-0-磺基-a -D-吡喃葡糖 基)-(1 —4)-0-(2,3-二-0-甲基-/S-D-吡喃葡糖基-糖醛 I 酸)-(1 — 4)-0-(2,3,6-三-0-磺基-6^-0-吡喃葡糖基)_(1 ! —4)-0-(2,6-脫水-5-(:-羧基-3-0-甲基-/3-0-吡喃甘露 I 糖基)-(l —4)-2-0-磺基-3,6-二-0-甲基-a -D-吡喃葡糖 甞,鋼鹽。 | · 甲基0-(2,3,4-三-0-甲基-6-0-磺基-a -D-吡喃葡糖 基)-(l —4)-0-(2,3-二-0·甲基-/5-D-吡喃葡糖基-糖醛 酸)-(1 — 4)-0-(2,3,6-三-0-磺基-“-0-吡喃葡糖基)-(1 —4)-0-(2,6-脫水-5-0-羧基-3-0-甲基-/5-0-吡喃甘露 糖基)-(1 —4)-2,3-二-0-磺基-6-0-甲基-a -D-吡喃葡糖 | 答,#3鹽。 • 甲基0-(2,3,4-三-0-甲基-6-0磺基_ a -D-吡喃葡糖 基)-(l —4)-0-(2,3-二-0-甲基-/3-D“比喃葡糖基-糖醛 酸HI —4)-0-(2,3,6-三-Ο-磺基-a -D-吡喃葡糖基)-(1 —4)-〇-(2,6-脫水-5-(:-羧基-3-0-甲基-冷-〇-吡喃甘露 糖基)-(1 ~^ 4) - 2,6 - —《 - 0 -石買基-3 - 0 -甲基 (2 - D - ?比喃葡糖 ! 荅,鋼鹽。 ! · 甲基0-(2,3,4-三-0-甲基-6-0-磺基-a -D-吡喃葡糖 | 基)-(1 —4)-0-(2,3-二-0-甲基-/5 -Dj比喃葡糖基-糖醛 酸)-(1 — 4)-0-(2,3,6-三-0-磺基-6^-0-外匕喃葡糖基)_(1 ~>4)-〇-(2,7-脫水-5<-羧基-6-脫氧-3-0-甲基-/3-0-七 ! 吡喃甘露糖基HI —4)-2,3,6-三磺基-α -D-叶匕喃葡 -2- 本纸張尺度適用中國國家標準(CNS) Α4規格(210 X 297公釐) 550267 A8 B8 C8 D8中請專利範圍 糖替,鐵鹽。 4 .〜種具有抗Xa因子活性且對AT III有親合性之醫藥組合 物,其含有作為活性成分的根據申請專利範圍第1至3项 任一項之五糖,其為與醫藥上可接受的鹼所成的鹽的鹽 的形式或是酸的形式,合併有或混合有醫藥上可接受的 無毒性賦形劑。 5·根據申請專利範圍第4項之醫藥組合物,其為劑量單位形 式,其中活性成分是與至少一種醫藥賦形劑混合。 6·根據申請專利範圍第5項之醫藥組合物,其中每一劑量單 位含0.1至100毫克活性成分。 7·根據申請專利範圍第6項之醫藥組合物,其中每一劑量單 位含0.5至50毫克活性成分。 8 ·根據申請專利範圍第1或2項之五糖,其係用於製備因凝 血障礙所引起的疾病之藥物。 本紙張又度適用中國國家樣準(CMS) A4規格(210 X 297公釐)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9800514A FR2773801B1 (fr) | 1998-01-19 | 1998-01-19 | Nouveaux pentasaccharides, procedes pour leurs preparations et compositions pharmaceutiques les contenant |
Publications (1)
Publication Number | Publication Date |
---|---|
TW550267B true TW550267B (en) | 2003-09-01 |
Family
ID=9521913
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW088100711A TW550267B (en) | 1998-01-19 | 1999-01-18 | Novel pentasaccharides, processes for their preparation and pharmaceutical compositions containing them |
Country Status (39)
Country | Link |
---|---|
US (1) | US6670338B1 (zh) |
EP (1) | EP1049706B1 (zh) |
JP (1) | JP4695756B2 (zh) |
KR (1) | KR100533565B1 (zh) |
CN (1) | CN1172948C (zh) |
AR (1) | AR012779A1 (zh) |
AT (1) | ATE241637T1 (zh) |
AU (1) | AU744137B2 (zh) |
BR (1) | BR9907100B1 (zh) |
CA (1) | CA2318326C (zh) |
CO (1) | CO4970823A1 (zh) |
CZ (1) | CZ299817B6 (zh) |
DE (1) | DE69908298T2 (zh) |
DK (1) | DK1049706T3 (zh) |
DZ (1) | DZ2706A1 (zh) |
EE (1) | EE04194B1 (zh) |
EG (1) | EG23760A (zh) |
ES (1) | ES2200494T3 (zh) |
FR (1) | FR2773801B1 (zh) |
GT (1) | GT199900006A (zh) |
HK (1) | HK1029999A1 (zh) |
HR (1) | HRP20000479B1 (zh) |
HU (1) | HU228335B1 (zh) |
IL (2) | IL137240A0 (zh) |
MY (1) | MY125636A (zh) |
NO (1) | NO316894B1 (zh) |
NZ (1) | NZ505614A (zh) |
PL (1) | PL191098B1 (zh) |
PT (1) | PT1049706E (zh) |
RU (1) | RU2193040C2 (zh) |
SA (1) | SA99191114B1 (zh) |
SI (1) | SI1049706T1 (zh) |
SK (1) | SK284176B6 (zh) |
TR (1) | TR200002077T2 (zh) |
TW (1) | TW550267B (zh) |
UA (1) | UA61124C2 (zh) |
UY (1) | UY25357A1 (zh) |
WO (1) | WO1999036428A1 (zh) |
ZA (1) | ZA99357B (zh) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2814463B1 (fr) * | 2000-09-22 | 2002-11-15 | Sanofi Synthelabo | Nouveaux polysaccharides a activite antithrombotique comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine |
AU2003302238A1 (en) | 2002-12-03 | 2004-06-23 | Axys Pharmaceuticals, Inc. | 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors |
CN100338084C (zh) * | 2004-07-02 | 2007-09-19 | 北京大学 | 抑制异种器官移植免疫排斥反应的五糖抗原的合成方法 |
FR2874924B1 (fr) | 2004-09-09 | 2006-12-01 | Sanofi Aventis Sa | Hexadecasaccharides biotinyles, leur preparation et leur utilisation therapeutique |
TWI403334B (zh) | 2004-12-23 | 2013-08-01 | Merck Sharp & Dohme | 包含生物素殘基之抗血栓雙重抑制劑 |
TWI376234B (en) | 2005-02-01 | 2012-11-11 | Msd Oss Bv | Conjugates of a polypeptide and an oligosaccharide |
US20070191306A1 (en) * | 2005-08-17 | 2007-08-16 | Bristol-Myers Squibb Company | FACTOR Xa INHIBITOR FORMULATION AND METHOD |
EP1908768A1 (en) * | 2006-10-05 | 2008-04-09 | Endotis Pharma | Anticoagulant compounds |
KR101529061B1 (ko) | 2008-05-30 | 2015-06-16 | 모멘타 파머슈티컬스 인코포레이티드 | 당류 구조물, 그리고 이러한 구조물의 제조 및 사용 방법 |
EP2323605A4 (en) * | 2008-09-10 | 2014-02-05 | Syneron Medical Ltd | TRANSDERMAL RELEASE OF OLIGOSACCHARIDES |
US8288515B2 (en) | 2009-07-31 | 2012-10-16 | Reliable Biopharmaceutical Corporation | Process for preparing Fondaparinux sodium and intermediates useful in the synthesis thereof |
US8420790B2 (en) | 2009-10-30 | 2013-04-16 | Reliable Biopharmaceutical Corporation | Efficient and scalable process for the manufacture of Fondaparinux sodium |
WO2012172104A1 (en) | 2011-06-17 | 2012-12-20 | Endotis Pharma | Synthetic pentasaccharides having short half-life and high activity |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0300099A1 (en) * | 1987-07-20 | 1989-01-25 | Akzo N.V. | New pentasaccharides |
IL102758A (en) * | 1991-08-23 | 1997-03-18 | Akzo Nv | Glycosaminoglycanoid derivatives, their preparation and pharmaceutical compositions comprising them |
ES2147216T3 (es) * | 1993-09-01 | 2000-09-01 | Akzo Nobel Nv | Bisconjugados que comprenden dos sacaridos y un grupo de union. |
FR2751334B1 (fr) * | 1996-07-19 | 1998-10-16 | Sanofi Sa | Polysaccharides synthetiques, procede pour leur preparation et compositions pharmaceutiques les contenant |
-
1998
- 1998-01-19 FR FR9800514A patent/FR2773801B1/fr not_active Expired - Lifetime
-
1999
- 1999-01-13 SI SI9930357T patent/SI1049706T1/xx unknown
- 1999-01-13 ES ES99900525T patent/ES2200494T3/es not_active Expired - Lifetime
- 1999-01-13 RU RU2000119750/04A patent/RU2193040C2/ru not_active IP Right Cessation
- 1999-01-13 DE DE69908298T patent/DE69908298T2/de not_active Expired - Lifetime
- 1999-01-13 DK DK99900525T patent/DK1049706T3/da active
- 1999-01-13 CN CNB998041386A patent/CN1172948C/zh not_active Expired - Fee Related
- 1999-01-13 JP JP2000540143A patent/JP4695756B2/ja not_active Expired - Fee Related
- 1999-01-13 NZ NZ505614A patent/NZ505614A/xx not_active IP Right Cessation
- 1999-01-13 EE EEP200000421A patent/EE04194B1/xx unknown
- 1999-01-13 PL PL341874A patent/PL191098B1/pl unknown
- 1999-01-13 BR BRPI9907100-2B1A patent/BR9907100B1/pt not_active IP Right Cessation
- 1999-01-13 PT PT99900525T patent/PT1049706E/pt unknown
- 1999-01-13 UA UA2000074112A patent/UA61124C2/xx unknown
- 1999-01-13 DZ DZ990007A patent/DZ2706A1/xx active
- 1999-01-13 SK SK1079-2000A patent/SK284176B6/sk not_active IP Right Cessation
- 1999-01-13 KR KR10-2000-7007850A patent/KR100533565B1/ko not_active IP Right Cessation
- 1999-01-13 IL IL13724099A patent/IL137240A0/xx active IP Right Grant
- 1999-01-13 AU AU19746/99A patent/AU744137B2/en not_active Ceased
- 1999-01-13 CA CA2318326A patent/CA2318326C/en not_active Expired - Fee Related
- 1999-01-13 HU HU0102042A patent/HU228335B1/hu not_active IP Right Cessation
- 1999-01-13 TR TR2000/02077T patent/TR200002077T2/xx unknown
- 1999-01-13 AT AT99900525T patent/ATE241637T1/de active
- 1999-01-13 US US09/600,516 patent/US6670338B1/en not_active Expired - Lifetime
- 1999-01-13 WO PCT/FR1999/000045 patent/WO1999036428A1/fr active IP Right Grant
- 1999-01-13 CZ CZ20002636A patent/CZ299817B6/cs not_active IP Right Cessation
- 1999-01-13 EP EP99900525A patent/EP1049706B1/fr not_active Expired - Lifetime
- 1999-01-16 EG EG5599A patent/EG23760A/xx active
- 1999-01-18 AR ARP990100171A patent/AR012779A1/es active IP Right Grant
- 1999-01-18 UY UY25357A patent/UY25357A1/es not_active IP Right Cessation
- 1999-01-18 TW TW088100711A patent/TW550267B/zh active
- 1999-01-18 MY MYPI99000205A patent/MY125636A/en unknown
- 1999-01-19 GT GT199900006A patent/GT199900006A/es unknown
- 1999-01-19 ZA ZA9900357A patent/ZA99357B/xx unknown
- 1999-01-19 CO CO99002525A patent/CO4970823A1/es unknown
- 1999-02-27 SA SA99191114A patent/SA99191114B1/ar unknown
-
2000
- 2000-07-10 IL IL137240A patent/IL137240A/en not_active IP Right Cessation
- 2000-07-17 NO NO20003661A patent/NO316894B1/no not_active IP Right Cessation
- 2000-07-19 HR HR20000479A patent/HRP20000479B1/xx not_active IP Right Cessation
-
2001
- 2001-02-12 HK HK01101002A patent/HK1029999A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001291960B2 (en) | Polysaccharides with antithrombotic activity comprising at least a covalent bond with biotin or a biotin derivative | |
TW550267B (en) | Novel pentasaccharides, processes for their preparation and pharmaceutical compositions containing them | |
RU2167163C2 (ru) | Синтетические полисахариды, способ их получения и содержащая их фармацевтическая композиция | |
KR100513196B1 (ko) | 합성 폴리사카라이드, 그의 제조 방법 및 그를 함유한제약 조성물 | |
JP3594990B2 (ja) | 3−デオキシオリゴ糖、その製造方法およびそれを含有する医薬組成物 | |
Xu et al. | Efficient synthesis of a library of heparin tri-and tetrasaccharides relevant to the substrate of heparanase | |
KR101223364B1 (ko) | 비오틴화 16당류, 그의 제조 방법 및 그의 용도 | |
EP2721044B1 (en) | Synthetic pentasaccharides having short half-life and high activity | |
Desoky | Synthesis of Sulfated Carbohydrates Using Sulfuryl Imidazolium Salts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GD4A | Issue of patent certificate for granted invention patent |